A carregar...
Cost of Refractory Crohn’s Disease Before and After Ustekinumab Utilization
BACKGROUND: Crohn’s disease (CD) is associated with major health services utilization and costs. Between 2012 and 2015, ustekinumab was used off-label in Quebec, Canada for treatment of refractory CD. AIMS: We assessed the direct medical cost of adult CD patients in the 1-year pre- and 1-year postus...
Na minha lista:
| Publicado no: | J Can Assoc Gastroenterol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7678737/ https://ncbi.nlm.nih.gov/pubmed/33241178 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jcag/gwz025 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|